Taxotere, Eloxatin Flat Sales Show Challenges Of Crowding Oncology Market
Executive Summary
Nearly flat sales growth in the U.S. for Sanofi-Aventis' Eloxatin and Taxotere may be indicative of challenges facing manufacturers as more and more oncologics enter the market